Skip to main content

Role of Topical Calcineurin Inhibitors on Atopic Dermatitis of Children

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

Besides the traditional topical treatment of mild and moderate forms of atopic dermatitis (AD), which includes the daily use of emollients and the intermittent use of topical corticosteroids (TCSs) as anti-inflammatory drugs, a new group of drugs has recently been introduced to control the inflammatory phase of the disease: topical calcineurin inhibitors (TCIs). Although the efficacy of TCSs is evident, prolonged unrestricted use is limited by local and systemic side effects. The major risk in children is the hypothalamic-pituitary-adrenal gland suppression, due to the higher percutaneous absorption of the TCSs.

TCIs selectively block the activity of calcineurin, a serin/threonine protein phosphatase regulated by cellular calcium first detected in skeletal muscle and brain. Within the past few years, calcineurin has been implicated in a wide range of biological responses including lymphocyte activation, neuronal and muscle development, and morphogenesis of heart valves. TCIs disrupt the intracellular signalling towards NF-AT by forming a complex with macrophilin-12. This complex inhibits the activity of calcineurin, thereby preventing the dephosphorylation of NF-AT and so interfering with the transcription of several genes. The nuclear component of NF-AT, binding to its nuclear counterpart, is essential for the transcription of various genes, including interleukin (IL)-2 and other proinflammatory cytokines.

Recent findings about the therapeutic efficacy of TCIs have provided a possible alternative to TCSs in the treatments of mild to severe forms of AD.

Keywords: Topical calcineurin inhibitors; atopic dermatitis; pimecrolimus; tacrolimus

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986707780831032

Affiliations: Department of Pediatrics, Via Massarenti 11, 40138 Bologna, Italy.

Publication date: June 1, 2007

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2007/00000014/00000014/art00009
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more